RIGL: VEPPANU launch widens portfolio as higher costs weigh on third-quarter earnings
RIGL reported third-quarter revenue of $80.9M, but net income and EPS fell amid higher costs. VEPPANU brought in $6.6M in initial sales.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
RIGL posted third-quarter revenue of $80.9M. Net income and EPS declined year over year as costs rose, according to a summary published by TradingView. VEPPANU has launched and generated initial sales of $6.6M. Liquidity stood at $99.3M, and data for R289 along with dose selection are expected by year-end.
why it matters
For investors, the key question is whether the new VEPPANU product can offset higher spending and preserve the cash cushion. R289 data due by year-end will be the next important marker for the stock, though the report offers no sales trends beyond the quarter.
market impact
RIGL shares: higher costs pressure profit, while the VEPPANU launch adds revenue
tags
instruments
sources
- RIGL: VEPPANU launch expands the portfolio as higher costs weigh on Q3 earnings — TradingView, 5 November 2026 at 21:08 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗